{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:31:12Z","timestamp":1792978272889,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41587-024-02487-7","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T05:03:21Z","timestamp":1732511001000},"page":"1783-1789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Intravenous administration of blood\u2013brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system"],"prefix":"10.1038","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1630-9453","authenticated-orcid":false,"given":"Chang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-2487","authenticated-orcid":false,"given":"Yonger","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xucheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5105-6709","authenticated-orcid":false,"given":"Zhengwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinglingge","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-019X","authenticated-orcid":false,"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Kopell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-6858","authenticated-orcid":false,"given":"Alexander W.","family":"Charney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-2000","authenticated-orcid":false,"given":"Eric J.","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-0659","authenticated-orcid":false,"given":"Yizhou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"2487_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129\u2013138 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2487_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1021\/ar2002123","volume":"45","author":"RL Juliano","year":"2012","unstructured":"Juliano, R. L., Ming, X. & Nakagawa, O. The chemistry and biology of oligonucleotide conjugates. Acc. Chem. Res. 45, 1067\u20131076 (2012).","journal-title":"Acc. Chem. Res."},{"key":"2487_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125\u2013140 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2487_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222\u2013229 (2017).","journal-title":"Nat. Biotechnol."},{"key":"2487_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2487_CR6","doi-asserted-by":"publisher","first-page":"eaaz8204","DOI":"10.1126\/sciadv.aaz8204","volume":"6","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles. Sci. Adv. 6, eaaz8204 (2020).","journal-title":"Sci. Adv."},{"key":"2487_CR7","doi-asserted-by":"publisher","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blood\u2013brain barrier-penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci. Adv. 6, eabc7031 (2020).","journal-title":"Sci. Adv."},{"key":"2487_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","volume":"37","author":"JF Alterman","year":"2019","unstructured":"Alterman, J. F. et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat. Biotechnol. 37, 884\u2013894 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2487_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","volume":"39","author":"T Nagata","year":"2021","unstructured":"Nagata, T. et al. Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood\u2013brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol. 39, 1529\u20131536 (2021).","journal-title":"Nat. Biotechnol."},{"key":"2487_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. 40, 1500\u20131508 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2487_CR11","doi-asserted-by":"publisher","first-page":"eadi2245","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker, S. J. et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood\u2013brain barrier. Sci. Transl. Med. 16, eadi2245 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2487_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2487_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat. Rev. Drug Discov. 20, 362\u2013383 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2487_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu, D. et al. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct. Target. Ther. 8, 217 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2487_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","volume":"7","author":"E Nance","year":"2022","unstructured":"Nance, E., Pun, S. H., Saigal, R. & Sellers, D. L. Drug delivery to the central nervous system. Nat. Rev. Mater. 7, 314\u2013331 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"2487_CR16","doi-asserted-by":"publisher","first-page":"2208018","DOI":"10.1002\/adma.202208018","volume":"35","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Overcoming the blood\u2013brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules. Adv. Mater. 35, 2208018 (2023).","journal-title":"Adv. Mater."},{"key":"2487_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","volume":"31","author":"G Pornnoppadol","year":"2024","unstructured":"Pornnoppadol, G. et al. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. Cell Chem. Biol. 31, 361\u2013372.e368 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2487_CR18","doi-asserted-by":"publisher","first-page":"eaay1359","DOI":"10.1126\/scitranslmed.aay1359","volume":"12","author":"MS Kariolis","year":"2020","unstructured":"Kariolis, M. S. et al. Brain delivery of therapeutic proteins using an Fc fragment blood\u2013brain barrier transport vehicle in mice and monkeys. Sci. Transl. Med. 12, eaay1359 (2020).","journal-title":"Sci. Transl. Med."},{"key":"2487_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1083\/jcb.138.4.877","volume":"138","author":"B Dehouck","year":"1997","unstructured":"Dehouck, B. et al. A new function for the LDL receptor: transcytosis of LDL across the blood\u2013brain barrier. J. Cell Biol. 138, 877\u2013889 (1997).","journal-title":"J. Cell Biol."},{"key":"2487_CR20","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/mp500258p","volume":"11","author":"RJ Boado","year":"2014","unstructured":"Boado, R. J., Lu, J. Z., Hui, E. K.-W. & Pardridge, W. M. Insulin receptor antibody\u2013sulfamidase fusion protein penetrates the primate blood\u2013brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol. Pharm. 11, 2928\u20132934 (2014).","journal-title":"Mol. Pharm."},{"key":"2487_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41563-023-01481-9","volume":"22","author":"DE Tylawsky","year":"2023","unstructured":"Tylawsky, D. E. et al. P-selectin-targeted nanocarriers induce active crossing of the blood\u2013brain barrier via caveolin-1-dependent transcytosis. Nat. Mater. 22, 391\u2013399 (2023).","journal-title":"Nat. Mater."},{"key":"2487_CR22","doi-asserted-by":"publisher","first-page":"eabc4397","DOI":"10.1126\/sciadv.abc4397","volume":"6","author":"X Tian","year":"2020","unstructured":"Tian, X. et al. On the shuttling across the blood-brain barrier via tubule formation: mechanism and cargo avidity bias. Sci. Adv. 6, eabc4397 (2020).","journal-title":"Sci. Adv."},{"key":"2487_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17783-4","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid \u03b2 species in vivo. Nat. Commun. 11, 4052 (2020).","journal-title":"Nat. Commun."},{"key":"2487_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. & Gatch, M. B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull. 126, 74\u201388 (2016).","journal-title":"Brain Res. Bull."},{"key":"2487_CR25","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00381-015-2725-3","volume":"31","author":"LM Hoffman","year":"2015","unstructured":"Hoffman, L. M. et al. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Child Nerv. Syst. 31, 1283\u20131289 (2015).","journal-title":"Child Nerv. Syst."},{"key":"2487_CR26","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2011.35.7806","volume":"29","author":"M Fouladi","year":"2011","unstructured":"Fouladi, M. et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J. Clin. Oncol. 29, 3529\u20133534 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2487_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0014-2999(93)90282-M","volume":"237","author":"A Bachy","year":"1993","unstructured":"Bachy, A. et al. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur. J. Pharmacol. 237, 299\u2013309 (1993).","journal-title":"Eur. J. Pharmacol."},{"key":"2487_CR28","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1073\/pnas.1037392100","volume":"100","author":"WT Kimberly","year":"2003","unstructured":"Kimberly, W. T. et al. \u03b3-Secretase is a membrane protein complex comprised of presenilin, nicastrin, APH-1, and PEN-2. Proc. Natl Acad. Sci. USA 100, 6382\u20136387 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2487_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nature13567","volume":"512","author":"P Lu","year":"2014","unstructured":"Lu, P. et al. Three-dimensional structure of human \u03b3-secretase. Nature 512, 166\u2013170 (2014).","journal-title":"Nature"},{"key":"2487_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature14892","volume":"525","author":"X-C Bai","year":"2015","unstructured":"Bai, X.-C. et al. An atomic structure of human \u03b3-secretase. Nature 525, 212\u2013217 (2015).","journal-title":"Nature"},{"key":"2487_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang, G. et al. Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell 184, 521\u2013533(2021).","journal-title":"Cell"},{"key":"2487_CR32","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1021\/bi602509c","volume":"46","author":"S Zhou","year":"2007","unstructured":"Zhou, S., Zhou, H., Walian, P. J. & Jap, B. K. Regulation of \u03b3-secretase activity in Alzheimer\u2019s disease. Biochemistry 46, 2553\u20132563 (2007).","journal-title":"Biochemistry"},{"key":"2487_CR33","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.1523\/JNEUROSCI.1381-10.2010","volume":"30","author":"JJ Cook","year":"2010","unstructured":"Cook, J. J. et al. Acute \u03b3-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-\u03b2 production to alternative APP fragments without amyloid-\u03b2 rebound. J. Neurosci. 30, 6743\u20136750 (2010).","journal-title":"J. Neurosci."},{"key":"2487_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","volume":"76","author":"HF Dovey","year":"2001","unstructured":"Dovey, H. F. et al. Functional \u03b3-secretase inhibitors reduce \u03b2-amyloid peptide levels in brain. J. Neurochem. 76, 173\u2013181 (2001).","journal-title":"J. Neurochem."},{"key":"2487_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31799-y","volume":"13","author":"G Lu","year":"2022","unstructured":"Lu, G. et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat. Commun. 13, 4214 (2022).","journal-title":"Nat. Commun."},{"key":"2487_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fncel.2019.00230","volume":"13","author":"NL Stone","year":"2019","unstructured":"Stone, N. L., England, T. J. & O\u2019Sullivan, S. E. A novel transwell blood brain barrier model using primary human cells. Front. Cell. Neurosci. 13, 230 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"2487_CR37","doi-asserted-by":"publisher","first-page":"1065193","DOI":"10.3389\/fncel.2022.1065193","volume":"16","author":"C Barberio","year":"2022","unstructured":"Barberio, C. et al. A human-derived neurovascular unit in vitro model to study the effects of cellular cross-talk and soluble factors on barrier integrity. Front. Cell. Neurosci. 16, 1065193 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"2487_CR38","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science 384, 1220\u20131227 (2024).","journal-title":"Science"},{"key":"2487_CR39","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41593-019-0491-3","volume":"22","author":"M Ximerakis","year":"2019","unstructured":"Ximerakis, M. et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat. Neurosci. 22, 1696\u20131708 (2019).","journal-title":"Nat. Neurosci."},{"key":"2487_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/nat.2013.0443","volume":"23","author":"G Hung","year":"2013","unstructured":"Hung, G. et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23, 369\u2013378 (2013).","journal-title":"Nucleic Acid Ther."},{"key":"2487_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24232-3","volume":"12","author":"J Li","year":"2021","unstructured":"Li, J. et al. Conservation and divergence of vulnerability and responses to stressors between human and mouse astrocytes. Nat. Commun. 12, 3958 (2021).","journal-title":"Nat. Commun."},{"key":"2487_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41586-019-1506-7","volume":"573","author":"RD Hodge","year":"2019","unstructured":"Hodge, R. D. et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61\u201368 (2019).","journal-title":"Nature"},{"key":"2487_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead, R. J., Shan, N., Reiser, H. J., Marshall, F. & Shaw, P. J. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 22, 185\u2013212 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2487_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41582-023-00867-2","volume":"19","author":"SA Goutman","year":"2023","unstructured":"Goutman, S. A., Savelieff, M. G., Jang, D.-G., Hur, J. & Feldman, E. L. The amyotrophic lateral sclerosis exposome: recent advances and future directions. Nat. Rev. Neurol. 19, 617\u2013634 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"2487_CR45","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772\u20131775 (1994).","journal-title":"Science"},{"key":"2487_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng0596-43","volume":"13","author":"AG Reaume","year":"1996","unstructured":"Reaume, A. G. et al. Motor neurons in Cu\/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13, 43\u201347 (1996).","journal-title":"Nat. Genet."},{"key":"2487_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hum.2015.122","volume":"27","author":"F Borel","year":"2015","unstructured":"Borel, F. et al. Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1G93A mice and nonhuman primates. Hum. Gene Ther. 27, 19\u201331 (2015).","journal-title":"Hum. Gene Ther."},{"key":"2487_CR48","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558\u20133567 (2018).","journal-title":"J. Clin. Invest."},{"key":"2487_CR49","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","volume":"30","author":"I Krop","year":"2012","unstructured":"Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307\u20132313 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2487_CR50","doi-asserted-by":"publisher","first-page":"950","DOI":"10.15252\/emmm.201607265","volume":"9","author":"Y Ran","year":"2017","unstructured":"Ran, Y. et al. \u03b3\u2010secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol. Med. 9, 950\u2013966 (2017).","journal-title":"EMBO Mol. Med."},{"key":"2487_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JAD-2011-101065","volume":"25","author":"A Haapasalo","year":"2011","unstructured":"Haapasalo, A. & Kovacs, D. M. The many substrates of presenilin\/\u03b3-secretase. J. Alzheimers Dis. 25, 3\u201328 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"2487_CR52","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958\u201316961 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"2487_CR53","doi-asserted-by":"publisher","first-page":"eadg6265","DOI":"10.1126\/sciadv.adg6265","volume":"9","author":"Y Yu","year":"2023","unstructured":"Yu, Y. et al. An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Sci. Adv. 9, eadg6265 (2023).","journal-title":"Sci. Adv."},{"key":"2487_CR54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41583-023-00717-6","volume":"24","author":"D Nikom","year":"2023","unstructured":"Nikom, D. & Zheng, S. Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat. Rev. Neurosci. 24, 457\u2013473 (2023).","journal-title":"Nat. Rev. Neurosci."},{"key":"2487_CR55","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1021\/acs.chemrev.3c00611","volume":"124","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Chemically modified platforms for better RNA therapeutics. Chem. Rev. 124, 929\u20131033 (2024).","journal-title":"Chem. Rev."},{"key":"2487_CR56","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ymthe.2020.12.022","volume":"29","author":"J Scharner","year":"2021","unstructured":"Scharner, J. & Aznarez, I. Clinical applications of single-stranded oligonucleotides: current landscape of approved and in-development therapeutics. Mol. Ther. 29, 540\u2013554 (2021).","journal-title":"Mol. Ther."},{"key":"2487_CR57","doi-asserted-by":"publisher","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","volume":"64","author":"B Xiong","year":"2021","unstructured":"Xiong, B. et al. Strategies for structural modification of small molecules to improve blood\u2013brain barrier penetration: a recent perspective. J. Med. Chem. 64, 13152\u201313173 (2021).","journal-title":"J. Med. Chem."},{"key":"2487_CR58","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"2487_CR59","doi-asserted-by":"publisher","first-page":"E6490","DOI":"10.1073\/pnas.1621240114","volume":"114","author":"SM Sarett","year":"2017","unstructured":"Sarett, S. M. et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl Acad. Sci. USA 114, E6490\u2013E6497 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2487_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8969","volume":"6","author":"K Nishina","year":"2015","unstructured":"Nishina, K. et al. DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6, 7969 (2015).","journal-title":"Nat. Commun."},{"key":"2487_CR61","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ymthe.2020.10.017","volume":"29","author":"Y Asami","year":"2021","unstructured":"Asami, Y. et al. Efficient gene suppression by DNA\/DNA double-stranded oligonucleotide in vivo. Mol. Ther. 29, 838\u2013847 (2021).","journal-title":"Mol. Ther."},{"key":"2487_CR62","doi-asserted-by":"publisher","first-page":"eabm8011","DOI":"10.1126\/sciadv.abm8011","volume":"8","author":"Y Zou","year":"2022","unstructured":"Zou, Y. et al. Blood\u2013brain barrier-penetrating single CRISPR\u2013Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci. Adv. 8, eabm8011 (2022).","journal-title":"Sci. Adv."},{"key":"2487_CR63","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/nar\/gky037","volume":"46","author":"MR Hassler","year":"2018","unstructured":"Hassler, M. R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185\u20132196 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2487_CR64","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.xpro.2021.101019","volume":"2","author":"J Ouellette","year":"2021","unstructured":"Ouellette, J. & Lacoste, B. Isolation and functional characterization of primary endothelial cells from mouse cerebral cortex. STAR Protoc. 2, 101019 (2021).","journal-title":"STAR Protoc."}],"updated-by":[{"DOI":"10.1038\/s41587-025-02601-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000}}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02487-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T19:03:02Z","timestamp":1762974182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-024-02487-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2487"],"URL":"https:\/\/doi.org\/10.1038\/s41587-024-02487-7","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41587-025-02601-3","URL":"https:\/\/doi.org\/10.1038\/s41587-025-02601-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.D. is a scientific advisor for Arbor Biotechnologies, siRNAgen Therapeutics and Moonwalk Biosciences. Y.D. is a cofounder and holds equity in Immunanoengineering Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}